SCHEMBL14736907

SCHEMBL14736907

CCCCOC(=O)C1(COc2c(-c3ccc4c(c3)CNC4=O)ccc(OC)c2OC)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 4/20 0.40
TDP2 O95551 2/20 0.36
MAPKAPK2 P49137 1/20 0.36
POLQ O75417 1/20 0.35
CNR2 P34972 1/20 0.34
MAPK1 P28482 3/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
KMT2A Q03164 2/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
HTT P42858 1/20 0.34
GSK3B P49841 2/20 0.33
DAPK3 O43293 1/20 0.33
NTRK1 P04629 1/20 0.33
PIM1 P11309 1/20 0.33
FLT3 P36888 1/20 0.33
ROCK1 Q13464 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
PRKCI P41743 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2588539 0.95 PDE4D (0.38) PDE4DTDP2MAPKAPK2POLQGSK3B
SCHEMBL2591418 0.92 GSK3B (0.35) PDE4DTDP2MAPKAPK2POLQGSK3B
SCHEMBL2584422 0.92 PDE4D (0.38) PDE4DTDP2MAPKAPK2POLQGSK3B
SCHEMBL2591133 0.91 POLQ (0.38) PDE4DTDP2MAPKAPK2POLQKMT2A
SCHEMBL2591736 0.89 GSK3B (0.34) PDE4DTDP2MAPKAPK2POLQGSK3B
SCHEMBL2591397 0.89 POLQ (0.40) PDE4DTDP2MAPKAPK2POLQGSK3B
SCHEMBL2591396 0.88 POLQ (0.37) PDE4DTDP2MAPKAPK2POLQKMT2A
SCHEMBL2591236 0.87 PDE4D (0.39) PDE4DTDP2MAPKAPK2POLQGSK3B
SCHEMBL2586322 0.87 POLQ (0.35) PDE4DTDP2MAPKAPK2POLQGSK3B
SCHEMBL2586295 0.86 PDE4D (0.41) PDE4DTDP2MAPKAPK2POLQCNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A PDE4D 10/4885TDP2 54/4885MAPKAPK2 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.